Clinical Trials

More documents

Recommendations

Info

❘❙❚■ Chapter 35 | Use of TablesFigure 1. Primary and secondary trial endpoints [3].Placebon/NMagnesiumn/NFavorstreatmentFavorscontrolOdds ratio(95% CI)PGlobal outcome0.95 (0.80, 1.13)0.59Barthel score
<strong>Clinical</strong> <strong>Trials</strong>: A Practical Guide ■❚❙❘ratios (0.99 for our row). Detailed reading of the statistical methods section statesthat the authors have adjusted their odds ratios for the stratification variables,namely age group, the side of the body affected by the stroke, time torandomization, and type of stroke – hence the reason for the discrepancy betweenthe two ratios. Ideally, this adjustment should have been noted in a footnote tothe table.The text also explains the reason for the missing numbers against the “globaloutcome” (because it is a composite odds ratio for death or disability), whichmight again have been included in a table footnote. The figure within the tablegives no additional information to the text of the table (representing merely theodds ratios and CIs graphically), but presents it in a more user-friendly way,allowing the reader to quickly appreciate which outcomes are improved by theactive treatment.In this example, there is a slight suggestion that the death rate is increased, sincethe estimated odds ratio is above 1, as well as most of the CI. However, the factthat the CI does encompass the odds ratio of 1 (ie, from 0.98 to 1.53) and theP-value = 0.07 (ie, >0.05) suggests that this is also compatible with no differencein death rates between the treated and control arms. Most other outcomes,including the global outcome, show very little difference between the two arms,with CIs including the odds ratio of 1, and nothing approaching statisticalsignificance. For key outcome results, it is becoming traditional to present thisvery useful combination of both a figure and table.On occasions it is necessary to incorporate subheadings within a table. Table 2shows an example of such a table, based on cost data from a randomized trialfor the evaluation of a new model of routine antenatal care. The costs areappropriately reported separately for each country and also separately, usingsubheadings, for the provider’s costs and the costs borne by the women. As well asgiving descriptive statistics for the costs according to treatment (ie, means andstandard deviations), the table also directly reports a comparison between the twomodels, ie, the authors quote a mean difference with 95% CIs. The use of thissummary measure means that the reader can deduce the mean cost saving thatwould accrue by using the new method on, say, 100 women (by multiplying themean difference in costs by 100), and the level of precision of this estimate,based on differing costs for different women (ie, attributable to sampling variation,as reported in the 95% CI).The cost units are given in the footnotes (since they do not apply to all the datain any one column), as well as detailed information needed to interpret thisinformation fully, namely on how local currencies were converted into US$. Such395
Page 8:
❘❙❚■ ContributorsStephen L
Page 11 and 12:
Clinical Trials: A Practical Guide
Page 13 and 14:
Page 15:
Page 19 and 20:
■■❚❙❘Chapter 1RandomizedC
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 34 and 35:
❘❙❚■ Chapter 2 | Uncontroll
Page 36 and 37:
Page 38 and 39:
Page 41 and 42:
■■❚❙❘Chapter 3Protocol De
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
■■❚❙❘Chapter 4EndpointsAm
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
■■❚❙❘Chapter 5Patient Sel
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
■■❚❙❘Chapter 6Source and
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
■■❚❙❘Chapter 7Randomizati
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91:
Page 94 and 95:
❘❙❚■ Chapter 8 | BlindingBl
Page 96 and 97:
❘❙❚■ Chapter 8 | BlindingTh
Page 98 and 99:
❘❙❚■ Chapter 8 | BlindingAs
Page 100 and 101:
❘❙❚■ Chapter 9 | Sample Siz
Page 102 and 103:
Page 104 and 105:
Page 107:
■■❚❙❘Part IIAlternativeTr
Page 110 and 111:
❘❙❚■ Chapter 10 | Crossover
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100
Page 120 and 121:
❘❙❚■ Chapter 11 | Factorial
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
❘❙❚■ Chapter 12 | Equivalen
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
❘❙❚■ Chapter 13 | Bioequiva
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
❘❙❚■ Chapter 14 | Noninferi
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
❘❙❚■ Chapter 15 | Cluster R
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
152
Page 172 and 173:
❘❙❚■ Chapter 16 | Multicent
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 183 and 184:
■■❚❙❘Part IIIBasics ofSta
Page 185 and 186:
■■❚❙❘Chapter 17Types of D
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
■■❚❙❘Chapter 18Significan
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
■■❚❙❘Chapter 19Comparison
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
■■❚❙❘Chapter 20Comparison
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
■■❚❙❘Chapter 21Analysis o
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
■■❚❙❘Part IVSpecial Trial
Page 273 and 274:
■■❚❙❘Chapter 22Intention-
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
■■❚❙❘Chapter 23Subgroup A
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
■■❚❙❘Chapter 24Regression
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
■■❚❙❘Chapter 25Adjustment
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
■■❚❙❘Chapter 26Confoundin
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
■■❚❙❘Chapter 27Interactio
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
■■❚❙❘Chapter 28RepeatedMe
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
■■❚❙❘Chapter 29Multiplici
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
■■❚❙❘Chapter 30Missing Da
Page 359 and 360:
Page 361 and 362: Clinical Trials: A Practical Guide
Page 371 and 372: ■■❚❙❘Chapter 31Interim Mo
Page 381 and 382: ■■❚❙❘Chapter Part V32Repo
Page 383 and 384: ■■❚❙❘Chapter 32Overview o
Page 395 and 396: ■■❚❙❘Chapter 33Trial Prof
Page 403 and 404: ■■❚❙❘Chapter 34Presenting
Page 409 and 410: ■■❚❙❘Chapter 35Use of Tab
Page 411: Clinical Trials: A Practical Guide
Page 425 and 426: ■■❚❙❘Chapter 36Use of Fig
Page 445 and 446: ■■❚❙❘Chapter 37Critical A
Page 457 and 458: ■■❚❙❘Chapter 38Meta-Analy
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
■■❚❙❘GlossaryGlossary453
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
■■❚❙❘AbbreviationsAbbrevi
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
■■❚❙❘IndexIndex467
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
show all

Clinical Trials

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?